Value elements and methods of value-based pricing for drugs in Japan: a systematic review

IntroductionValue-based pricing (VBP) can be a promising tool for optimizing drug prices. However, there is no consensus on the specific value elements and pricing method that should be used for VBP.Areas coveredWe performed a systematic review and narrative synthesis to investigate the value elements and pricing method for VBP. The main inclusion criterion was that value elements, VBP method, and estimated prices for actual drugs were reported. We performed a search in MEDLINE and ICHUSHI Web. Eight articles met the selection criteria. Four studies adopted the cost-effectiveness analysis (CEA) approach and the others used different approaches. The CEA approach included the value elements of productivity, value of hope, real option value, disease severity, insurance value in addition to costs and quality-adjusted life years. The other approaches used efficacy, toxicity, novelty, rarity, research and development costs, prognosis, population health burden, unmet needs, and effectiveness. Each study used individual methods to quantify these broader value elements.Expert opinionBoth conventional and broader value elements are used for VBP. To allow VBP to be widely applied to various diseases, a simple, versatile method is preferable. Further research is needed to establish VBP method which enables to incorporate broader values.

Automated summary

This article investigates the value elements and pricing method for value-based pricing (VBP) and finds that there is no consensus on specific value elements and pricing methods. Some studies used the cost-effectiveness analysis approach, while others used different approaches, quantifying broader value elements with individual methods. Further research is needed to establish a VBP method that incorporates broader values.